Research · Sep 3, 2026
[KRC] Kilroy Realty Thesis 2026: A West-Coast-Office-and-Life-Science-REIT Compounder Rides AI-Tech Re-Acceleration
Kilroy Realty Corporation (NYSE: KRC), headquartered in Los Angeles, California, is a West-Coast-office-and-emerging-life-science-and-emerging-mixed-use-REIT providing distinctive multi-cycle Kilroy-Realty West-Coast-office-and-life-science-and-mixed-use services to West-Coast-Tech-tenant + Life-Science-tenant + multi-cycle-Class-A-office-and-life-science-and-mixed-use-tenant customer base. Distinctive multi-cycle John-B-Kilroy-and-Kilroy-Realty heritage: founded 1947 in Los Angeles-CA by John-B-Kilroy-Sr + multi-cycle-Kilroy-Realty entrepreneurs; January 1997 Kilroy-Realty-NYSE-IPO; multi-cycle 1997-2024 multi-cycle Kilroy-Realty + multi-cycle-disciplined-bolt-on-M&A + multi-cycle-emerging-Kilroy-Oyster-Point-life-science; 2024 Angela Aman CEO appointment. Multi-decade strategic-evolution: 1947-1997 John-B-Kilroy-Sr-and-Kilroy-Realty platform; January 1997 NYSE-IPO; 1997-2024 multi-cycle Kilroy-Realty + multi-cycle-disciplined-bolt-on-M&A + multi-cycle-emerging-Kilroy-Realty-West-Coast-multi-state + multi-cycle-emerging-Kilroy-Oyster-Point-life-science; 2024 Angela Aman CEO; 2020-2025 substantial multi-cycle post-COVID + multi-cycle-emerging-West-Coast-office-occupancy-cycle + emerging-AI-tech-tenant + emerging-life-science + emerging-mixed-use + multi-cycle-deleveraging-post-2020-COVID. Under CEO Angela Aman (since 2024, ~1+ year longtime Brixmor + multi-cycle-retail-REIT executive), FY2025 closes with selected various aggregate revenue ~$1.05-1.15B, adj. EBITDA-and-FFO ~$420-480M, adj. FFO/share ~$3.80-4.40, net debt ~$5.2-5.7B, and ~118-122M shares outstanding. The first deep-dive — West-Coast-office + emerging-life-science + emerging-mixed-use Class-A-office-and-life-science-and-mixed-use-REIT franchise — covers entire West-Coast-office + emerging-life-science + emerging-mixed-use REIT business + Kilroy-Realty-and-emerging-Kilroy-Realty positioning. Geographic + Property composition: ~16M+ sq-ft + ~120+ Class-A-office-and-life-science-and-mixed-use property-portfolio: San Diego-CA (substantial San-Diego + emerging-Kilroy-Oyster-Point-life-science); Los Angeles-CA (substantial Class-A-office-and-mixed-use); San Francisco-Bay-Area-CA (substantial Class-A-office-and-life-science); Seattle-WA + Austin-TX (substantial Class-A-office). Revenue mix: Class-A-Office ~70-80% (largest-business + emerging-AI-tech-tenant); Life-Science ~15-25% (Kilroy-Oyster-Point + emerging-life-science); Mixed-Use + Other ~5-10% (emerging-Kilroy-Sunset-Boulevard-mixed-use). Customer base: West-Coast-Tech-tenant (Alphabet-Google + Microsoft + Salesforce + Adobe + Meta + Apple + Amazon-AWS + Netflix + Snowflake + Splunk + emerging-AI-tech-tenant-OpenAI-and-Anthropic) + Life-Science-tenant (Genentech + Biogen + Bristol-Myers + Biotech) + emerging-AI-and-Tech-tenant. Multi-cycle-emerging-Kilroy-Oyster-Point-life-science + emerging-Kilroy-Sunset-Boulevard-mixed-use. Competes with Boston Properties (BXP most-direct-larger-Boston-Properties-Class-A-office-comp), Vornado Realty Trust (VNO), Cousins Properties (CUZ most-direct-Cousins-Properties-Sunbelt-office-comp), Highwoods Properties (HIW), Empire State Realty Trust (ESRT), Paramount Group (PGRE), SL Green (SLG), Hudson Pacific Properties (HPP most-direct-Hudson-Pacific-West-Coast-office-comp), Brandywine Realty Trust (BDN), Piedmont Office Realty (PDM), Brookfield Properties (BN), Tishman Speyer (private), Hines (private); life-science REIT Alexandria Real Estate Equities (ARE largest-US-life-science-REIT most-direct-Alexandria-Real-Estate-Equities-life-science-comp), BioMed Realty (Blackstone-acquired 2016), Healthpeak Properties (DOC + Physicians-Realty-2024-merger), Ventas (VTR), Welltower (WELL); West-Coast-Tech-tenant Alphabet-Google (GOOGL), Microsoft (MSFT), Salesforce (CRM), Adobe (ADBE), Meta (META), Apple (AAPL), Amazon (AMZN), Netflix (NFLX), Snowflake (SNOW), Splunk (Cisco-acquired 2024); life-science-tenant Genentech (Roche subsidiary), Biogen (BIIB), Bristol-Myers Squibb (BMY), Pfizer (PFE), Merck (MRK), AbbVie (ABBV), Eli Lilly (LLY), Amgen (AMGN), Gilead Sciences (GILD), Regeneron (REGN), Vertex Pharmaceuticals (VRTX), Moderna (MRNA). The second deep-dive — Angela-Aman + multi-cycle-Kilroy-Realty + multi-decade compounder thesis — covers Angela-Aman-CEO + Brixmor + multi-cycle-retail-REIT expertise, January-1997-NYSE-IPO + multi-cycle-disciplined-bolt-on-M&A + multi-cycle-emerging-Kilroy-Oyster-Point-life-science + emerging-Kilroy-Sunset-Boulevard-mixed-use, emerging-US-West-Coast-office-occupancy-recovery + emerging-AI-tech-tenant-re-acceleration + emerging-life-science + emerging-mixed-use structural-tailwinds. Multi-cycle-deleveraging-post-2020-COVID. Multi-decade compounder thesis combines John-B-Kilroy-and-Kilroy-Realty ~78+ year heritage, ~16M+ sq-ft + ~120+ Class-A-office-and-life-science-and-mixed-use property-portfolio, January-1997-NYSE-IPO + multi-cycle-disciplined-bolt-on-M&A + multi-cycle-emerging-Kilroy-Oyster-Point-life-science, Angela Aman + Brixmor expertise, multi-cycle reliable-and-emerging-growing-dividend + no-buyback + IG balance-sheet, emerging-US-West-Coast-office-occupancy-recovery + emerging-AI-tech-tenant + emerging-life-science + emerging-mixed-use structural-tailwinds. Capital position is IG (BBB-/BBB), dividend-reliable-and-emerging-growing, multi-cycle-deleveraging-post-2020-COVID: net debt ~$5.2-5.7B (~10-12x leverage), BBB-/BBB equivalent, $0.10-0.30B cash + undrawn revolver liquidity, FCF + AFFO ~$300-380M/yr deployed into capex ~$130-220M/yr + dividend (~$2.16/yr, ~5.0-7.5% yield, ~50-60% payout) + no buyback + multi-cycle-disciplined-bolt-on-M&A + emerging-Kilroy-Oyster-Point-life-science-and-Kilroy-Sunset-Boulevard-mixed-use development capex, ~118-122M shares. At ~$28-42 per share, equity value ~$3.4-5.1B, EV ~$8.6-10.8B, ~7-11x FFO/share and ~18-25x EV/EBITDA. Base case: West-Coast-office-occupancy-recovery constructive + emerging-AI-tech-tenant + emerging-life-science + emerging-mixed-use + revenue $1.10-1.20B + adj. EBITDA-and-FFO $440-510M + adj. FFO/share $3.90-4.60 + dividend hiked + multi-cycle-deleveraging + ~5-15% return. Bull case: West-Coast-office-occupancy-recovery accelerates + emerging-AI-tech-tenant inflects-substantially + emerging-life-science inflects + emerging-mixed-use inflects + revenue $1.15-1.30B + adj. EBITDA-and-FFO $480-580M + adj. FFO/share $4.20-5.20 + dividend hiked + selective-M&A + emerging-strategic-acquisition-target (Boston Properties + Brookfield-Properties + Blackstone-BioMed-Realty + Alexandria-Real-Estate-Equities interest) + re-rate 9-13x + 25-50%+ return + takeout-premium-upside. Bear case: West-Coast-office-occupancy-recovery disappoints + emerging-AI-tech-tenant disappoints + adj. FFO/share $2.80-3.30 + de-rate 5-7x + flat-to-substantially-negative.